KR20190054221A - Biocompatible polymeric thread with multi-function - Google Patents

Abstract

The present invention discloses a multifunctional biocompatible thread. The multifunctional biocompatible thread, which is partially or entirely inserted into a long hole of a needle and embedded in the skin, contains an inhibitory substance for inhibiting secretion or action of acetylcholine on the surface thereof. Accordingly, the secretion or action of acetylcholine can be precisely suppressed at a desired skin position, and skin can be continuously stimulated to increase efficiency of inducing the proliferation of cells or living tissues.

Description

Biocompatible polymeric thread with multi-function < RTI ID = 0.0 >

More particularly, the present invention relates to a multifunctional biocompatible thread which can precisely suppress the secretion or action of acetylcholine at a desired skin position, can continuously perform skin stimulation, To a multifunctional biocompatible chamber capable of improving the efficiency of the biosensor.

The sold-out procedure is also referred to as callus therapy. It does not cut the skin of the body and pulls the skin or muscle tightly to improve the wrinkles or to keep the skin tissue in a resilient state. It is widely used in surgery.

These stitching procedures use surgical sutures made of absorbable materials such as polylactic acid, polydiaxonone, lactic acid and glycolic acid, (Glycolic Acid), and the like, so that it is not necessary to remove the material after the procedure.

The stitching procedure is performed 3 to 6 months after being inserted into the body, and the rope is absorbed. The rope becomes a factor that causes the wound to be stimulated in the skin, thereby inducing secretion of the immune substance that heals the wound. After the body tissue is healed, the lifted state can be maintained by the rope, so that the stretched skin can be kept in a taut state or wrinkles can be improved.

This insertion procedure is completed by inserting a suture into a syringe such as a needle having a diameter of about 0.45 mm, inserting the suture into the skin, removing the syringe from the syringe, and implanting the suture in the skin.

That is, as can be seen from FIG. 6, such a book marking operation is obtained by spinning every ship having a predetermined diameter, as a general book-making room 1 is manufactured by pulling out a normal thread from a material absorbed in the body, One or more strands are mutually twisted together to constitute the yarn handling room 1. The yarn handling yarn 1 has a generally circular cross-sectional diameter, The knot 2 is formed.

In addition, Botox treatment is usually performed by injecting a substance that inhibits the secretion of acetylcholine or interferes with the action of injection into an injection site to improve the skin condition due to frequent use of muscle, .

However, such Botox has a problem that it is difficult to control the time for decomposing and absorbing or acting immediately after the operation because the injection needle is used exactly for the site to be sutured.

Accordingly, the technical problem to be solved by the present invention is to provide a method and an apparatus for inhibiting the secretion or action of acetylcholine precisely at a desired skin position, performing continuous skin irritation, and thereby improving the efficiency of induction of proliferation of cells or tissues Functional biocompatible chamber that is capable of providing a multi-functional biocompatibility.

Disclosure of the Invention In order to solve the above-described technical problem, the present invention provides a method for producing a botulinum toxin type A, acetyl hexapeptide, methionyl r-clostridium botulinum polypeptide-1 hexapeptide-40 or Botox hybrid protein, And then lyophilized and dried to provide a multifunctional biocompatible chamber.

According to one embodiment of the present invention, a material comprising botulinum toxin type A, acetyl hexapeptide, methionyl r-clostridium botulinum polypeptide-1 hexapeptide-40 or Botox hybrid protein is frozen in a fine powder at a low temperature environment Which may be dried and encapsulated.

According to another embodiment of the present invention, the encapsulation may be carried out using polylactic acid (PLLA), polylactic acid (PLA), polydioxanone (PDO), monocryl ), Polycarprolactone (PCL), poly glycolic acid (PGA), or poly lactic-co-glycolic acid (PLGA).

According to another embodiment of the present invention, a biocompatible chamber may be inserted into the core at the center of the chamber.

According to another embodiment of the present invention, the biocompatible chamber may be at least one selected from the group consisting of glycolide, glycolic acid, lactide, lactic acid, caprolactone, dioxanone, trimethylene carbonate and ethylene glycol.

According to another embodiment of the present invention, the length of the biocompatible chamber may be 0.5 mm to 20 cm.

According to another embodiment of the present invention, the suppression substance may be retained in a plurality of depressions provided on the surface of the biocompatible chamber.

According to another embodiment of the present invention, the depth of the depression may be 5 to 50% of the diameter of the biocompatible chamber.

According to another embodiment of the present invention, the inhibitory substance may be a botulinum toxin type A, acetyl hexapeptide, methionyl r-clostridium botulinum polypeptide-1 hexapeptide-40 or Botox hybrid protein.

According to another embodiment of the present invention, the inhibiting material may be encapsulated as a temporary protective layer.

According to another embodiment of the present invention, the temporary protective layer may be formed of at least one material selected from the group consisting of poly-L-lactic acid (PLLA), polylactic acid (PLA), polydioxanone (PDO) (Monocryl), polycaprolactone (PCL), polyglycolic acid (PGA), or poly lactic-co-glycolic acid (PLGA).

According to the multifunctional biocompatible yarn according to the present invention, the secretion or action of acetylcholine can be precisely suppressed at a desired skin position, and continuous skin irritation can be performed. Thus, proliferation of cells or tissues enhances induction efficiency .

FIG. 1 is a cross-sectional view showing a state where the biocompatible yarn according to the present invention is shortly dispersed in an injection solution and buried in the skin,
FIG. 2 is a cross-sectional view showing a state in which a part of the biocompatible thread according to the present invention is long,
3 is a cross-sectional view showing a shape in which inhibitory substances are dispersed in a medium layer on the surface of a biocompatible material of the present invention,
4 is a cross-sectional view showing a depression of a biocompatible chamber according to the present invention,
Figure 5 is a cross-sectional view of a shape coated with a surface media layer of a biocompatible chamber encapsulated with an inhibitory material according to the present invention,
6 is a perspective view showing a shape in which a conventional baring room is partly embedded in a needle.

Hereinafter, the present invention will be described in detail.

It is to be noted, however, that the technical terms used in the present invention are used only for describing specific embodiments, and are not intended to limit the present invention.

In addition, the technical terms used in the present invention should be construed in a sense generally understood by a person having ordinary skill in the art to which the present invention belongs, unless otherwise defined in the present invention, Or technical terms used in the present invention are erroneous technical terms that do not accurately represent the spirit of the present invention, it is to be understood that the technical terms used herein are not to be construed in a technical sense And the generic term used in the present invention should be construed in accordance with the predefined or prior context and should not be construed in an excessively reduced meaning, The expression of the plural, unless the context clearly dictates otherwise. In the present invention, terms such as " comprising " or " comprising " and the like should not be construed as encompassing various elements or various steps of the invention, It should be understood that the steps may not be included, or may be further comprised of additional components or steps, and in the description of the present invention, if it is determined that the detailed description of the related art is not sufficient to overcome the gist of the present invention A detailed description thereof will be omitted.

In addition, the drawing numbers shown in the drawings are denoted by the same reference numerals unless otherwise specified, and the description thereof may be omitted in the overlapping portions.

FIG. 1 is a cross-sectional view showing a state in which the biocompatible yarn according to the present invention is dispersed in an injectable solution and embedded in the skin when the biocompatible yarn according to the present invention is short. FIG. 2 is a cross- FIG. 3 is a cross-sectional view showing a state in which inhibitory substances are dispersed in a medium layer on the surface of the biocompatible seal according to the present invention, and FIG. 4 is a cross-sectional view showing a biocompatible FIG. 5 is a cross-sectional view showing a shape of the encapsulated inhibitory material according to the present invention and coated with the surface medium layer of the biocompatible chamber.

The multifunctional biocompatible chamber 100 according to the present invention is characterized in that a material comprising a botulinum toxin type A, acetyl hexapeptide, methionyl r-clostridium botulinum polypeptide-1 hexapeptide-40 or Botox hybrid protein is used in a low temperature environment And may be extruded and freeze-dried.

Here, freeze-drying means performing drying at a low temperature, for example, at a temperature of 30 DEG C or less, and can be changed depending on the material to be used.

In addition, the yarn may be a multi-filament drawn yarn as well as a monofilament, and the multifilament yarn may be useful for freeze-drying.

On the other hand, the material may be lyophilized as a powder to be prepared as a capsule, and the surface of the particles constituting the powder may be wrapped with a temporary protective layer.

The temporary protective layer may be formed of at least one selected from the group consisting of polylactic acid (PLLA), polylactic acid (PLA), polydioxanone (PDO), monocryl, polycaprolactone , polycarprolactone), polyglycolic acid (PGA), polylactic-co-glycolic acid (PLGA), and the like.

In addition, a biocompatible chamber may be inserted into the core at the center of the chamber.

The biochemical room is partly or wholly inserted into the elongated hole 210 of the needle 200 and is embedded in the skin. An inhibitory substance 300 for inhibiting the secretion or action of acetylcholine is provided on the surface of the biocompatible chamber Is included.

Such a biocompatible chamber 100 includes not only a conventional surgical thread or suture but also a thread capable of differentiating or engaging cells in the skin.

The biocompatible chamber 100 is a material that is embedded in the skin and can be used for cosmetic or skin damage. It is not particularly limited as long as it does not cause skin damage or necrosis in the skin. However, It is preferable that the material is decomposed in the skin and discharged to the outside of the skin after the lapse of time, and therefore materials that are decomposed in vivo are preferable, and glycolide, glycolic acid, lactide, lactic acid, caprolactone, dioxanone, trimethylene carbonate and ethylene (PLLA), polylactic acid (PLA), polydioxanone (PDO), polyoxyethylene (polyoxyethylene), and polyoxyethylene Polydioxanone, Monocryl, Polycarprolactone, Polyglycolic acid, PGCL or Polylactic-co-gl (PLGA) ycolic acid may be used.

The biocompatible chamber 100 may partially or wholly penetrate into the elongated hole 210 of the needle to enter the skin S. The needle may be used not only for a needle used for a conventional medical syringe, , It is possible to use sterilized skin entry needles which do not have an inflammatory reaction or other adverse effects on the cells and can preferably be a metal material, wherein the cells have genetic information in the human body used in a general sense, And includes units of a replicable structure.

The length of the biocompatible chamber 100 may be 0.5 mm to 20 cm and the diameter may be 0.05 mm to 0.5 mm. The biocompatible chamber 100 may partially or wholly enter the elongated biocompatible thread of the needle, And the biocompatible yarn can be a false-twist yarn obtained by stretching a multifilament with a biopolymer, and is stretched by a multifilament. Thus, the surface of the yarn can have a certain degree of depression 110. The depression will be described later .

Meanwhile, the biocompatible yarn may be spun through a spinneret, which is a conventional method, to prepare a single filament having a diameter of 5 to 30 mu m, which can be used as a multifilament by twisting a plurality of filaments. If the diameter of the single filament filament is 30 If it is more than 탆, the rigidity may increase, which may make handling in manufacturing or processing difficult.

If the length of the biocompatible chamber is less than 0.5 mm, it is easy to enter the needle into the skin and enter the skin, but the formation of the medium layer is not easy. On the other hand, if the length exceeds 20 cm, have.

Likewise, if the diameter of the biocompatible chamber is less than 0.005 mm, if the formation of the medium layer is not easy, on the other hand, if the diameter exceeds 0.5 mm, the handling property may become poor.

In addition, since the length of the biocompatible chamber is shortened and the entire length of the biopsy needle is shortened, it is difficult to be filled in the skin. Therefore, as in the case of the injection liquid L, .

Meanwhile, the inhibitory substance 300 is contained in the surface of the biocompatible chamber 100 to inhibit the secretion or action of acetylcholine, which is a neurotransmitter, at the motor nerve endings in skin cells or muscles. The botulinum toxin A Type acetyl hexapeptide, methionyl r-clostridium botulinum polypeptide-1 hexapeptide-40 or Botox hybrid protein.

The inhibitory substance 300 may be mixed with a solvent containing purified water, glycerin, butylene glycol, arginine, collagen, gelatin, laminin, fibronectin, galactose, chitosan or cellulose, The biosensor may be dipped in the solvent and coated on the surface of the biosensor so that the biosensor may be coated on the surface of the biosensor and dried to retain the inhibitor in the medium layer 310. [ have.

The medium layer 310 is prepared by uniformly mixing the solvent with the inhibitor and drying the same in a biocompatible chamber. The medium layer 310 is made of a polyglycolide lactide (PLGA) or poly L-lactic acid (PLLA).

On the other hand, the concavity 110 described above is formed on the surface of the strand when the strand is stretched in one strand or when the strand is stretched in a single strand and stretched to 5 to 50% of the thickness (diameter) of the biocompatible yarn (d), and the inhibitory substance can be retained in the depressed portion, so that the duration of intracellular cellular activity can be effectively controlled as compared with the case where it is dispersed in the medium layer on the surface.

If the depth d of the depression is less than 5% of the thickness (diameter) of the biocompatible chamber, the amount of the inhibitory substance retained is small, which makes it difficult to control the duration of cell activation, , The durability of the biocompatible seal itself becomes weak, so that the filament may be stuck to the filament, and the possibility of retaining the inhibitory substance may be lowered.

In addition, the inhibiting material 300 may be encapsulated with the temporary protecting layer 400, and the encapsulating material may be encapsulated so that the temporary protecting layer 400 may be decomposed as time elapses in the skin And the activity time of the inhibiting substance can be controlled.

The temporary protective layer 400 may be formed of a biodegradable material such as polylactic acid (PLLA), polylactic acid (PLA), polydioxanone (PDO) Monocryl, polycaprolactone, polyglycolic acid, or poly lactic-co-glycolic acid (PLGA) may be used.

The thickness t of the temporary protective layer 400 surrounding the inhibiting material may be 5 to 50 탆. If it is less than 5 탆, decomposition occurs easily in the skin, which may make it difficult to control the operation time. On the other hand, If it is more than 50 mu m, the time required for the binders of the medium layer 310 to dissolve is added to the operating time adjusting side, which increases the operation time, resulting in side reaction of the biodegradable material and inflammation in the skin.

A biocompatible chamber 100, a depression 110,
The needle 200, the elongated hole 210,
Inhibitory material 300, a medium layer 310,
The temporary protective layer 400,
Skin S, Injection L,
Depth of depression d, Temporary protective layer thickness t

Claims (11)

Characterized in that a material comprising botulinum toxin type A, acetyl hexapeptide, methionyl r-clostridium botulinum polypeptide-1 hexapeptide-40 or Botox hybrid protein is extruded in a low-temperature environment and then lyophilized. room.
A material comprising botulinum toxin type A, acetyl hexapeptide, methionyl r-clostridium botulinum polypeptide-1 hexapeptide-40 or Botox hybrid protein is lyophilized with a fine powder in a low-temperature environment and encapsulated Functional biocompatible thread.
3. The method of claim 2,
The encapsulation may be carried out using a polymeric material such as polylactic acid (PLLA), polylactic acid (PLA), polydioxanone (PDO), monocryl, polycaprolactone (PCL) ), Polyglycolic acid (PGA), or poly lactic-co-glycolic acid (PLGA).
The method according to claim 1,
And a biocompatible thread is inserted into the core thread at the center of the thread.
5. The method of claim 4,
Wherein the biocompatible chamber is at least one selected from the group consisting of glycolide, glycolic acid, lactide, lactic acid, caprolactone, dioxanone, trimethylene carbonate, and ethylene glycol.
5. The method of claim 4,
Wherein the length of the biocompatible chamber is 0.5 mm to 20 cm.
5. The method of claim 4,
Wherein the inhibitory substance is retained in a plurality of depressions provided on the surface of the biocompatible chamber.
8. The method of claim 7,
Wherein the depth of the depressed portion is 5 to 50% of the diameter of the biocompatible chamber.
5. The method of claim 4,
Wherein the inhibitory substance is a botulinum toxin type A, acetyl hexapeptide, methionyl r-clostridium botulinum polypeptide-1 hexapeptide-40 or Botox hybrid protein.
5. The method of claim 4,
Wherein the inhibitory substance is encapsulated as a temporary protective layer.
11. The method of claim 10,
The temporary protective layer may be formed of at least one selected from the group consisting of polylactic acid (PLLA), polylactic acid (PLA), polydioxanone (PDO), monocryl, polycaprolactone polycarprolactone), polyglycolic acid (PGA), or poly lactic-co-glycolic acid (PLGA).

Images